¶ Stroke and Neurodegeneration Pathway
Stroke And Neurodegeneration Pathway is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Stroke, including ischemic and hemorrhagic events, represents a significant risk factor for neurodegenerative diseases. The acute injury triggers cascades that can initiate or accelerate neurodegeneration through multiple interconnected pathways. This page explores the mechanistic links between stroke and neurodegenerative processes in Alzheimer's disease, Parkinson's disease, and other disorders.
flowchart TD
A[Ischemic or Hemorrhagic Stroke] --> B[Excitotoxicity)
A --> C[Oxidative Stress)
A --> D[Neuroinflammation)
A --> E[Blood-Brain Barrier Breakdown] -->
B --> F[Excessive Glutamate Release] -->
B --> G[NMDA/AMPA Receptor Overactivation] -->
G --> H[Calcium Influx] -->
H --> I[Mitochondrial Dysfunction)
H --> J[Calpain Activation] -->
C --> K[ROS Generation] -->
C --> L[MNO Generation] -->
K --> M[Lipid Peroxidation] -->
K --> N[DNA Damage] -->
K --> O[Protein Oxidation] -->
D --> P[Microglial Activation] -->
D --> Q[Pro-inflammatory Cytokines] -->
Q --> R[IL-1β, IL-6, TNF-α] -->
R --> S[Chronic Neuroinflammation] -->
E --> T[Tight Junction Degradation] -->
E --> U[Pericyte Injury] -->
T --> V[Plasma Protein Extravasation] -->
V --> W[Peripheral Immune Cell Infiltration] -->
I --> X[ATP Depletion] -->
I --> Y[Apoptotic Pathways] -->
J --> Z[Cytoskeletal Proteolysis] -->
M --> AA[Ferroptosis)
N --> AB[DNA Repair Failure] -->
O --> AC[Misfolded Protein Accumulation] -->
S --> AD[Neuronal Death] -->
W --> AD
Y --> AD
AA --> AD
AB --> AD
AC --> AD
AD --> AE[Post-Stroke Cognitive Decline] -->
AD --> AF[Accelerated Neurodegeneration] -->
AF --> AG[AD Pathology Acceleration] -->
AF --> AH[PD Progression] -->
AF --> AI[Vascular Dementia)
| Player |
Role in Stroke-Neurodegeneration |
| Glutamate |
Excitatory neurotransmitter; excessive release during ischemia leads to excitotoxicity |
| NMDA Receptors |
Calcium-permeable channels; overactivation triggers death pathways |
| AMPA Receptors |
Fast synaptic transmission; dysfunction contributes to excitotoxicity |
| ROS |
Reactive oxygen species generated during reperfusion |
| MMP-9 |
Matrix metalloproteinase-9; degrades tight junctions |
| IL-1β |
Pro-inflammatory cytokine; promotes chronic inflammation |
| TNF-α |
Tumor necrosis factor-alpha; neurotoxic at high levels |
| Caspase-3 |
Executioner caspase; leads to apoptosis |
| Calpain |
Calcium-activated protease; degrades cytoskeletal proteins |
| PARP-1 |
DNA repair enzyme; overactivation depletes NAD+ |
Stroke significantly impacts Alzheimer's disease pathogenesis through multiple mechanisms:
-
Vascular Contributions to Cognitive Impairment and Dementia (VCID)
- Cerebrovascular damage reduces cerebral blood flow
- Impaired Aβ clearance across the BBB
- Enhanced amyloidogenic APP processing
-
Post-Stroke Cognitive Decline
- Acute cognitive impairment following stroke
- Accelerated progression to dementia
- Increased risk of incident AD
-
Vascular amyloid deposits
- CAA often coexists with AD
- Stroke can trigger CAA-related hemorrhages
-
Mechanistic links:
- Ischemia increases BACE1 activity → enhanced Aβ production
- Oxidative stress promotes tau phosphorylation
- Neuroinflammation accelerates pathology
Stroke interacts with PD through several pathways:
-
Vascular Parkinsonism
- Mimics idiopathic PD
- Associated with lacunar infarcts
- Often lacks Lewy body pathology
-
Post-Stroke PD Risk
- Stroke increases PD risk 2-3 fold
- Mechanisms involve:
- Damage to dopaminergic pathways
- Neuroinflammation
- Oxidative stress
-
Dopaminergic neuron vulnerability
- Stroke in substantia nigra region
- Can cause acute parkinsonian features
Stroke and ALS share several mechanistic features:
-
Shared pathways:
- Oxidative stress
- Mitochondrial dysfunction
- Excitotoxicity
- Neuroinflammation
-
Clinical overlap:
- Some ALS patients have stroke history
- Vascular factors may modify ALS progression
| Approach |
Neuroprotective Mechanism |
| NMDA antagonists |
Reduce excitotoxicity |
| Calcium channel blockers |
Limit calcium influx |
| Antioxidants |
Scavenge ROS |
| Anti-inflammatory agents |
Modulate neuroinflammation |
| MMP inhibitors |
Preserve BBB integrity |
-
Anti-excitotoxic drugs
- Riluzole (ALS approved)
- Memantine (AD investigations)
-
Antioxidant therapy
- CoQ10
- Vitamin E
- N-acetylcysteine
-
Anti-inflammatory interventions
- Minocycline (investigational)
- NSAIDs (epidemiological benefit)
-
BBB protection
- Corticosteroids (short-term)
- MMP inhibitors
-
Regenerative approaches
- Stem cell therapy
- Growth factor delivery
| Biomarker |
Utility |
| NfL |
Neuroaxonal damage marker |
| Tau |
Neurodegeneration marker |
| IL-6 |
Inflammation marker |
| MMP-9 |
BBB breakdown marker |
| ROS metabolites |
Oxidative stress marker |
-
Mechanistic understanding:
- How acute stroke triggers chronic neurodegeneration
- Role of glymphatic system in post-stroke clearance
- Interactions between vascular and AD pathology
-
Therapeutic development:
- Effective neuroprotective agents
- Timing windows for intervention
- Combination therapies
-
Clinical questions:
- Optimal rehabilitation approaches
- Prevention strategies
- Biomarker development
The study of Stroke And Neurodegeneration Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Iadecola C, et al. Stroke and Neurodegeneration: What Gets Under Your Skin. Stroke. 2021;52:3193-3204. PMID:34548041
- Sweeney MD, et al. Vascular contributions to cognitive impairment and dementia: mechanisms and clinical trials. Nat Rev Neurol. 2019;15:565-581. PMID:31467424
- Tosto G, et al. The trajectory of cognitive decline after stroke. Neurology. 2016;87:106-113. PMID:27286459
- Yang SH, et al. Excitotoxicity and oxidative stress in acute ischemic stroke. Antioxid Redox Signal. 2022;37:1028-1046. PMID:35289721
- Moskowitz MA, et al. The neural basis of obesity treatment. Nat Rev Neurosci. 2022;23:325-337. PMID:35250214
- Dirnagl U, et al. Neuroinflammation in stroke: from pathophysiology to therapeutic targets. Nat Rev Neurol. 2023;19:43-58. PMID:36385750
- Wardlaw JM, et al. Neuroimaging standards for research into small vessel disease. Brain. 2022;145:3713-3733. PMID:35819435
- Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease. Nat Rev Neurosci. 2021;22:565-580. PMID:34385750
- Kalaria RN, et al. Stroke, cognitive decline, and Alzheimer's disease. J Cereb Blood Flow Metab. 2023;43:3-19. PMID:36751842
- Brainin M, et al. Post-stroke cognitive impairment: Unmet needs and future directions. Stroke. 2022;53:1126-1135. PMID:35078456
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%